Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
how much do u think this will get up?
what do u think how the share price will react?
CBMX
$CBMX COURT HAS TENTATIVELY RULED IN FAVOR OF THE DEFENDANTS AND AGAINST ALL CLAIMS OF THE PLAINTIFF
thank you for this great Post- I hope you will have long time to live
which one?
could it go to 10$?
where will it open?
it´s not tradeable under newl anymore... can´t buy
pls give me the nasdaq stockcode besides NEWL
pls give me the stocknumbers
are both holdings from US?
holla crapolla
MAYBE ALL THE MONEY IS GONE- BUT I really don´t think so
i´m not sure - but it could take weeks until this case get solved????????????????
why ouch????????? for the nakeds?
MBA_MS_Entrepreneurship $NEWL I confirm the T12 code is awaiting legal documents of the Magna deal. I do not have DD completed on financials (mess) or valuation
from stocktwits
does this make sense what u thinking?
OHHHHHHHH Jesus' won´tt help u anymore- be careful here
post your charts anywhere else- but not here!
hey clay- no more shorting here
earnings out
THE SHORTS WON´T HAVE A NICE MONDAY1111!!!!!!!!!!!
i GUESS THEY SETTLED-
MY GUESS
i FEEL IT- MUST BE THE RIGHT TIME TO BE IN IT
MY GUESS IS THEY WILL SETTLE SOON
pls give me break*
I`M out to 20$
CONGRATULATIONS**************************
thanx - bless you JJ
never hear to adam f!
http://www.ibj.com/lilly-said-to-be-willing-to-pay-37b-for-biotech-firm/PARAMS/article/45781
Eli Lilly and Co. is reportedly willing to pay as much as $3.7 billion to acquire a Cambridge, Mass.-based biotech company with a troubled leukemia drug, according to United Kingdom newspaper The Daily Mail.
The paper claims Indianapolis-based Lilly is leading a field of suitors for Ariad Pharmaceuticals Inc. that includes U.K.-based GlaxoSmithKline PLC and Ireland-based Shire PLC. All three firms made “friendly approaches” to Ariad, according to The Daily Mail, and are willing to pay up to $20 per share.
Ariad currently has 185.7 million shares outstanding, meaning such a purchase price would total $3.7 billion, more than double the company's current market value.
The reliability of the report is uncertain. The Daily Mail based its report on “whispers heard across the Pond” by “dealers.”
Lilly spokesman Mark Taylor declined to comment. “It is our policy at Lilly not to comment on market rumors or deal speculation,” Taylor wrote in an e-mail.
Nevertheless, Ariad’s stock has shot up on the news, which was first posted on The Daily Mail’s website last Wednesday evening. Shares rose 20 percent on Friday, to $8.99 each, the stock's biggest one-day gain since Dec. 18. That followed a 12-percent gain on Thursday.
Ariad launched a leukemia drug, called Iclusig, last year, then had to pull it from the market in October due to safety concerns. Ariad’s stock plunged and the company laid off 160 workers, according to the Boston Globe.
The leukemia drug was relaunched this month, but only for a limited number of patients with no other effective treatments.
Ariad executives say they plan to conduct more clinical trials to prove the drug’s safety and efficacy.
“There is significant value to be realized from Iclusig, AP26113, and the company’s highly efficient drug-discovery platform,” Jim Birchenough, an analyst at BMO Capital Markets, wrote in a research report, Bloomberg News reported. "AP26113 is a drug in development. Ariad assets are likely to attract large pharma interest
Monday, January 27, 2014
Health
Lilly said to be willing to pay $3.7B for biotech firm
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.